Liminatus Pharma, Inc. - 8-K Filing
Liminatus Pharma entered into a merger agreement with InnocsAI on May 17, 2026. Under terms of the deal, Liminatus will issue 1.6 billion shares at $0.20 per share and contingent value rights representing 20% of future proceeds from strategic sales or exits related to acquired assets. The merger aims to acquire oncology-focused biologic and cellular therapy programs including CAR-T candidates IBC101 (for B-cell malignancies) and INC101/INC102 (solid tumors), as well as a CS1 antibody platform for plasma cell targeting. (Items: 1.01 Entry into Material Definitive Agreement, 9.01 Financial Statements and Exhibits)
Tickers: $LIMN